KAPA (Kairos Pharma) Research & Development: $2.33 Mil (TTM As of Mar. 2026)


KAPA Kairos Pharma Ltd KAPA
15 GF Score
Price $0.38
View Full Analysis

What is Kairos Pharma Research & Development?

Kairos Pharma KAPA +7.48% 15 Research & Development is $2.33 Mil as of Mar. 2026. GuruFocus rates KAPA with a GF Score™ of 15/100.

Research & Development is the aggregate amount of research and development expenses during the year. Kairos Pharma's Research & Development for the three months ended in Mar. 2026 was $0.68 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $2.33 Mil.

Kairos Pharma  (AMEX:KAPA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Kairos Pharma Research & Development Related Terms

Kairos Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Kairos Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kairos Pharma Research & Development Chart

Kairos Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.18 0.09 0.08 0.41 2.14

Kairos Pharma Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.50 0.61 0.54 0.68
KAPA
15GF Score
Kairos Pharma Ltd KAPA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kairos Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $2.33 Mil mean?
Kairos Pharma (KAPA) has a Research & Development of $2.33 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Kairos Pharma and its competitors.
Is Kairos Pharma's Research & Development too high?
Kairos Pharma's current Research & Development is $2.33 Mil. Overall, Kairos Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Kairos Pharma's Research & Development compare to IMNN and HCWB?
Kairos Pharma's Research & Development of $2.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Kairos Pharma and its competitors. Kairos Pharma's current Research & Development is $2.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kairos Pharma stock overvalued right now?
Kairos Pharma (KAPA) has a current Research & Development of $2.33 Mil. The current Research & Development is $2.33 Mil. Kairos Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Kairos Pharma (KAPA), the current Research & Development is $2.33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kairos Pharma Business Description

Address 2355 Westwood Boulevard, No. 139, Los Angeles, CA, USA, 90064
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
15GF Score

Get the complete analysis for KAPA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price